Product Name :
MYCMI-6
Description:
MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5 μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis.
CAS:
681282-09-7
Molecular Weight:
373.41
Formula:
C20H19N7O
Chemical Name:
3-[(E)-2-(9-amino-7-ethoxyacridin-3-yl)diazen-1-yl]pyridine-2, 6-diamine
Smiles :
CCOC1=CC2=C(C=C1)N=C1C=C(C=CC1=C2N)/N=N/C1=CC=C(N)N=C1N
InChiKey:
QNWGRUNKGVWOTA-CYYJNZCTSA-N
InChi :
InChI=1S/C20H19N7O/c1-2-28-12-4-6-15-14(10-12)19(22)13-5-3-11(9-17(13)24-15)26-27-16-7-8-18(21)25-20(16)23/h3-10H,2H2,1H3,(H2,22,24)(H4,21,23,25)/b27-26+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50Product information|CAS Number: 681282-09-7|Molecular Weight: 373.{{Caffeic acid phenethyl ester} medchemexpress|{Caffeic acid phenethyl ester} Apoptosis|{Caffeic acid phenethyl ester} Biological Activity|{Caffeic acid phenethyl ester} Purity|{Caffeic acid phenethyl ester} manufacturer|{Caffeic acid phenethyl ester} Epigenetic Reader Domain} 41|Formula: C20H19N7O|Synonym:|NSC354961|Chemical Name: 3-[(E)-2-(9-amino-7-ethoxyacridin-3-yl)diazen-1-yl]pyridine-2, 6-diamine|Smiles: CCOC1=CC2=C(C=C1)N=C1C=C(C=CC1=C2N)/N=N/C1=CC=C(N)N=C1N|InChiKey: QNWGRUNKGVWOTA-CYYJNZCTSA-N|InChi: InChI=1S/C20H19N7O/c1-2-28-12-4-6-15-14(10-12)19(22)13-5-3-11(9-17(13)24-15)26-27-16-7-8-18(21)25-20(16)23/h3-10H,2H2,1H3,(H2,22,24)(H4,21,23,25)/b27-26+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 2.4 mg/mL (6.43 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Anti-Mouse PD-1 Antibody} medchemexpress|{Anti-Mouse PD-1 Antibody} Immunology/Inflammation|{Anti-Mouse PD-1 Antibody} Protocol|{Anti-Mouse PD-1 Antibody} References|{Anti-Mouse PD-1 Antibody} custom synthesis|{Anti-Mouse PD-1 Antibody} Autophagy} |Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|MYCMI-6 (NSC354961) (6.25 μM; 48 hours) selectively suppresses MYC-driven tumor cell growth with high efficacy. MYCMI-6 significantly inhibits growth of Burkitt’s lymphoma cells (Mutu, Daudi and ST486) – another classical example of a MYC-driven tumor, having translocations of MYC to one of the immunoglobulin loci – in a dose-dependent manner with an average GI50 of 0.PMID:32935999 5 μM. Treatment of MCF7 cells with the MYCMI-6 for 24 hours significantly decreased MYC:MAX isPLA signals to 7%. Titration showed an IC50 for inhibition of MYC:MAX of less than 1.5 μM for MYCMI-6 by isPLA. MYCMI-6 inhibits the MYC:MAX heterodimer formation with an IC50 of 3.8 μM. MYCMI-6 efficiently inhibits anchorage-independent growth of MYCN-amplified neuroblastoma cells with GI50 values of In Vivo:|MYCMI-6 (20 mg/kg; i.p.; daily for 1-2 weeks) induces massive apoptosis and reduces tumor cell proliferation, tumor microvasculature density and MYC:MAX interaction in a MYC-dependent xenograft tumor model.|References:|Castell A, et al. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Sci Rep. 2018 Jul 3;8(1):10064.Products are for research use only. Not for human use.|